• Mashup Score: 3

    PURPOSE Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). METHODS This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). RESULTS A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observ

    Tweet Tweets with this article
    • đź‘€ Tisotumab vedotin combined with chemotherapy and #Immunotherapy shows encouraging activity in recurrent #CervicalCancer. 👉 https://t.co/OUrr6uLfFE #gyncsm #ADC #ImmunoOnc https://t.co/e4IARUGGRt

  • Mashup Score: 1

    The manufacturer is pulling the drug from the market at the request of the FDA following disappointing results from a large phase 3 confirmatory trial.

    Tweet Tweets with this article
    • #BCMA #ADC belanatamab withdrawn from the US. P3 confirmatory trial DREAMM3 (belantamab vs. PomDex) for #RRMM showed no PFS advantage (HR, 1.03; 95% CI, 0.72 – 1.47). #FDA #AcceleratedApproval mechanism works as it should!!! https://t.co/6zAp0pXgj7 https://t.co/AjKeDDnH2L

  • Mashup Score: 1

    Listen to this episode from Clinical Papers Podcast on Spotify. O DESTINY-Breast04 Ă© o primeiro RCT a benefĂ­cios clinicamente significativos para pacientes com câncer de mama metastático HER2 low.Como regra geral, pacientes com câncer de mama avançado e baixos nĂ­veis de expressĂŁo de HER2 (HER2 low) sĂŁo considerados como HER2-negativos porque as terapias direcionadas a HER2 geralmente se mostram…

    Tweet Tweets with this article
    • Em mais um Podcast do @ClinicalPapers recebo o Dr. Carlos dos Anjos para conversar sobre o #destinybreast04 e suas implicações para a prática clĂ­nica. ImperdĂ­vel! #cancerdemama #breastcancer #trastuzumabederuxtecan #adc Para ouvir 👉🏽👉🏽 https://t.co/vUZNbOMAoG

  • Mashup Score: 18

    Degrader-antibody conjugates (DACs) are novel entities that combine a proteolysis targeting chimera (PROTAC) payload with a monoclonal antibody via some type of chemical linker. This review provides a current summary of the DAC field. Many general aspects associated with the creation and biological performan

    Tweet Tweets with this article
    • Check out Degrader-antibody conjugates : novel entities that combine a proteolysis targeting chimera (eg #PROTAC) payload with a monoclonal #antibody, this is yet a an emerging #ADC play in #cancer. https://t.co/MMUqo6FN8K https://t.co/D9khvApCfp